Medical Design Technology
Published on Medical Design Technology (https://www.mdtmag.com)

Home > Roche and Life Technologies Corporation Sign New PCR IVD Licenses

Roche and Life Technologies Corporation Sign New PCR IVD Licenses

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Life Technologies Corporation (LTC) announced today that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.

Under these two agreements, Roche has granted LTC an in vitro diagnostics product license to all of Roche's patents for real-time PCR (polymerase chain reaction) as well as other important PCR-related technology in the diagnostics field. Also covered in these agreements are reagents and methods of using SYBR Green I technology, melting curve analysis for real-time PCR, and rights to use high-resolution melting-curve analysis (HRM) technology in the diagnostics field.

Financial terms of the settlement were not disclosed.

The melting curve analysis is a technique for analysis of PCR products. After amplification, the resulting PCR product is slowly heated. Each double-stranded DNA has its own specific melting temperature (Tm) which is defined as the temperature at which 50% of the DNA becomes single stranded. By measurement of Tm using an intercalating dye, variations in the amplified DNA can be identified.

This valuable intellectual property portfolio has been extensively licensed by Roche in cooperation with Idaho Technology, Inc.

Paul Brown, Head of Roche Molecular Diagnostics said "Roche has a broad, active out-licensing program for its PCR-based intellectual property portfolio. By continuing to out-license this technology, we contribute to the development of well-validated techniques within the diagnostics field." About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs.

Genentech, United States, is a wholly owned member of the Roche Group.

Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For media inquiries please contact Corporate Communications at 888-545-2443 SOURCE Roche -0- 02/22/2012 /Web Site: http://www.roche.com (OTC-PINK:RHHBY / Swiss:RO) / CO: Roche; Life Technologies Corporation ST: California IN: MTC SU: LIC PRN -- SF57272 -- 0000 02/22/2012 17:00:00 EDT http://www.prnewswire.c

Content Item Type: 
News [1]
Meta Canonical URL: 
http://www.mdtmag.com/news/2012/02/roche-and-life-technologies-corporation-sign-new-pcr-ivd-licenses
Summary: 
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Life Technologies Corporation (LTC) announced today that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications. Under these two agreements, Roche has granted LTC an in vitro diagnostics product...
Contributed Author: 
The Associated Press
Legacy NID: 
105 366

Deeper Insights

<% if ( rc.ss_related_image_url != null ){ %>
?cmpid=regwallcontent&utm_source=Deeper%20Insights">">
<% } %>

?cmpid=regwallcontent&utm_source=Deeper%20Insights" + ""><%- rc.label %>

<% if ( rc.ss_search_logo != null ){ %>
">
<% } %>
Advertisement
googletag.cmd.push(function() { googletag.display("dfp-ad-clone_of_wallpaper"); });
(function() { var _fbq = window._fbq || (window._fbq = []); if (!_fbq.loaded) { var fbds = document.createElement('script'); fbds.async = true; fbds.src = '//connect.facebook.net/en_US/fbds.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(fbds, s); _fbq.loaded = true; } _fbq.push(['addPixelId', '745881082149515']); })(); window._fbq = window._fbq || []; window._fbq.push(['track', 'PixelInitialized', {}]);
(function(d,s,i,r) { if (d.getElementById(i)){return;} var n=d.createElement(s),e=d.getElementsByTagName(s)[0]; n.id=i;n.src='//js.hs-analytics.net/analytics/'+(Math.ceil(new Date()/r)*r)+'/1743435.js'; e.parentNode.insertBefore(n, e); })(document,"script","hs-analytics",300000);

Connect with Medical Design Technology

  • Facebook
  • Twitter
  • YouTube

Resources

  • About Us
  • Advertising Info
  • Contact Us
  • Contributor Guidelines
  • Digital Editions
  • Directory FAQs
  • Privacy Policy
  • Product Announcement Form
  • Subscriptions
  • Terms & Conditions

Topics

  • Cardiovascular
  • Diabetes
  • Home Healthcare
  • Implantables
  • Medical Diagnostics
  • Neurology
  • Oncology
  • Orthopedics
  • Pain Management
  • Prosthetics
  • Regenerative Medicine
  • Surgical
  • Wearables

© Copyright 2018 Advantage Business Marketing

var _qevents = _qevents || []; (function() { var elem = document.createElement('script'); elem.src = (document.location.protocol == "https:" ? "https://secure" : "http://edge") + ".quantserve.com/quant.js"; elem.async = true; elem.type = "text/javascript"; var scpt = document.getElementsByTagName('script')[0]; scpt.parentNode.insertBefore(elem, scpt); })(); _qevents.push({ qacct:"p-jsEPJWTckjCbE" });
Quantcast
googletag.cmd.push(function () { googletag.display("dfp-ad-roadblock_modal"); });
"" style="border: 0px; vertical-align: bottom;">
googletag.cmd.push(function() { googletag.display("dfp-ad-roadblock_modal"); });

Source URL: https://www.mdtmag.com/news/2012/02/roche-and-life-technologies-corporation-sign-new-pcr-ivd-licenses

Links
[1] https://www.mdtmag.com/content-item-types/news